院前大剂量糖皮质激素对院外心脏骤停复苏后患者血流动力学的影响:STEROHCA试验亚组研究
本文是随机、安慰剂对照2期STEROHCA试验的亚组研究,比较院外心脏骤停复苏后立即单次院前注射甲泼尼龙250 mg与安慰剂的血流动力学效应。纳入114例入院时仍昏迷且存活至ICU的患者(糖皮质激素组56例,安慰剂组58例)。ICU入室后48小时内糖皮质激素组去甲肾上腺素累积用量较低(平均差-0.04 mcg/kg/min,95%CI -0.07至-0.01,p=0.02);入室后12-24小时糖皮质激素组MAP较高(平均差6-7 mmHg,95%CI 1至12)、VIS较低(平均差-4.2至-3.8,95%CI -8.1至0.3)、VIS/MAP比较低(平均差-0.10至-0.07,95%CI -0.16至-0.01),心率无重大差异(平均差-4至-3,95%CI -11至3)。两组肺动脉导管测量无差异。作者结论:院前大剂量糖皮质激素治疗与复苏后OHCA患者去甲肾上腺素用量减少相关。
要点
- 院外心脏骤停复苏后立即院前单次甲泼尼龙250 mg,ICU入室后48小时内去甲肾上腺素累积用量较安慰剂低(平均差-0.04 mcg/kg/min,95%CI -0.07至-0.01,p=0.02)。
- 入室后12-24小时,甲泼尼龙组MAP较安慰剂组高6-7 mmHg(95%CI 1至12),VIS较低(平均差-4.2至-3.8,95%CI -8.1至0.3),VIS/MAP比较低(平均差-0.10至-0.07,95%CI -0.16至-0.01)。
- 入室后12-24小时两组心率无重大差异(平均差-4至-3,95%CI -11至3)。
- 入室后30-48小时上述治疗差异仍存在但幅度较小且统计不确定性增加。
- 两组肺动脉导管测量的心脏功能指标无差异。
适用人群与场景
- 院外心脏骤停复苏后入院时仍昏迷且存活至ICU的患者(糖皮质激素组n=56,安慰剂组n=58)。
- 研究场景为院前及ICU入室后48小时内。
处置流程与药物剂量
- 院外心脏骤停复苏后立即院前单次注射甲泼尼龙250 mg(与安慰剂对照)。
- 根据原文推荐,使用血管升压药维持平均动脉压(MAP)高于65 mmHg。
研究设计与关键结果
- 研究类型:随机、安慰剂对照、2期试验(STEROHCA)的亚组研究;纳入114例入院时仍昏迷且存活至ICU的院外心脏骤停复苏后患者,糖皮质激素组56例,安慰剂组58例。
- 主要结局:ICU入室至48小时去甲肾上腺素累积用量(mcg/kg/min),糖皮质激素组较安慰剂组低(平均差-0.04 mcg/kg/min,95%CI -0.07至-0.01,p=0.02);ICU入室时两组结局无差异。
- 次要结局:入室后12-24小时,糖皮质激素组MAP较高(平均差6-7 mmHg,95%CI 1至12),VIS较低(平均差-4.2至-3.8,95%CI -8.1至0.3),VIS/MAP比较低(平均差-0.10至-0.07,95%CI -0.16至-0.01),心率无重大差异(平均差-4至-3,95%CI -11至3)。
- 入室后30-48小时上述差异仍存在但幅度较小且统计不确定性增加;两组肺动脉导管测量无差异。
证据类型、等级与局限
- 证据类型:随机、安慰剂对照、2期试验的亚组研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:院前大剂量糖皮质激素治疗与复苏后OHCA患者去甲肾上腺素用量减少相关。
- 对急诊/ICU实践:本亚组研究提示院前单次甲泼尼龙250 mg可能降低ICU 48小时内去甲肾上腺素累积用量并改善12-24小时血流动力学指标(MAP、VIS、VIS/MAP比),但30-48小时差异幅度较小且统计不确定性增加,两组肺动脉导管测量无差异。
指南或共识出处
- STEROHCA试验亚组研究;试验注册号EudraCT 2020-000855-11,ClinicalTrials.gov NCT04624776。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Following resuscitated out-of-hospital cardiac arrest (OHCA), inflammatory markers are significantly elevated and associated with hemodynamic instability and organ dysfunction. Vasopressor support is recommended to maintain a mean arterial pressure (MAP) above 65 mmHg. Glucocorticoids have anti-inflammatory effects and may lower the need for vasopressors. This study aimed to assess the hemodynamic effects of prehospital high-dose glucocorticoid treatment in resuscitated comatose OHCA patients.
METHODS: The STEROHCA trial was a randomized, placebo-controlled, phase 2 trial comparing one prehospital injection of methylprednisolone 250 mg with placebo immediately after resuscitated OHCA. In this sub-study, we included patients who remained comatose at admission and survived until intensive care unit (ICU) admission. The primary outcome was cumulated norepinephrine use from ICU admission until 48 h reported as mcg/kg/min. Secondary outcomes included hemodynamic status characterized by MAP, heart rate, vasoactive-inotropic score (VIS), and the VIS/MAP-ratio as well as cardiac function assessed by pulmonary artery catheter measurements. Linear mixed-model analyses were performed to evaluate mean differences between treatment groups at all follow-up times.
RESULTS: A total of 114 comatose OHCA patients were included (glucocorticoid: n = 56, placebo: n = 58) in the sub-study. There were no differences in outcomes at ICU admission. From the time of ICU admission up to 48 h post-admission, patients in the glucocorticoid group cumulated a lower norepinephrine use (mean difference - 0.04 mcg/kg/min, 95% CI - 0.07 to - 0.01, p = 0.02). Moreover, after 12-24 h post-admission, the glucocorticoid group demonstrated a higher MAP with mean differences ranging from 6 to 7 mmHg (95% CIs from 1 to 12), a lower VIS (mean differences from - 4.2 to - 3.8, 95% CIs from - 8.1 to 0.3), and a lower VIS/MAP ratio (mean differences from - 0.10 to - 0.07, 95% CIs from - 0.16 to - 0.01), while there were no major differences in heart rate (mean differences from - 4 to - 3, 95% CIs from - 11 to 3). These treatment differences between groups were also present 30-48 h post-admission but to a smaller extent and with increased statistical uncertainty. No differences were found in pulmonary artery catheter measurements between groups.
CONCLUSIONS: Prehospital treatment with high-dose glucocorticoid was associated with reduced norepinephrine use in resuscitated OHCA patients.
TRIAL REGISTRATION: EudraCT number: 2020-000855-11; submitted March 30, 2020. URL: https://www.
CLINICALTRIALS: gov ; Unique Identifier: NCT04624776.
参考来源
- Obling LER, Beske RP, Meyer MAS, et al. Effect of prehospital high-dose glucocorticoid on hemodynamics in patients resuscitated from out-of-hospital cardiac arrest: a sub-study of the STEROHCA trial. Crit Care. 2024. PMID: 38254130. doi:10.1186/s13054-024-04808-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。